| Name | Title | Contact Details |
|---|
Introba is one of the worlds largest building engineering and consulting firms with more than 1,000 employees in offices across the United States, Canada, the United Kingdom, Serbia, and Australia. Committed to reshaping the world, our problem solvers combine cutting-edge digital solutions with emerging innovations and industry-leading sustainability strategies to transform the built environment. We collaborate with our clients to create living systems that are smart, secure, resilient, and connected – spaces that uplift communities, protect the health of the planet, and adapt to meet the demands of the future.
Axolight is a lighting company, based in Italy and the United States, which designs and produces high-end decorative design lamps. Handmade in Italy Each Axolight product, whether it derives from mass production or from a customized request, is designed, developed, tested and assembled by hand at the company workshop in Venice - Scorzè.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
gm3 is the leading web3-native professional services firm. We are dedicated to being the trusted partner of choice for companies and investors looking to navigate the exciting world of web3. Our mission is to provide expert consulting services that empower our clients to unlock the full potential of this transformative technology. gm3 Ventures connects Founders & Investors. For aspiring entrepreneurs, we offer a comprehensive range of financing services tailored to your specific needs. For investors, we provide access to diversified investment opportunities in the web3 ecosystem. With our rigorous due diligence process and curated network, we ensure quality deal flow. gm3 Research specializes in high-end, commissioned research and whitepaper curation across the web3, decentralized finance and technology spaces. Our commitment to excellence is led by Crypto Punk and Harvard University PhD, Dr. Michael Frisch. Together with our team of field experts, we illuminate the path to informed decision-making in the dynamic landscape of web3. gm3 Advisory provides tailored advice and strategic guidance to unlock the potential of web3 for both traditional companies exploring the space and web3-native companies looking to structure and scale their businesses. gm3 Curation offers luxury concierge services across physical art, digital art and high-end fashion. Our creative agency partnership has curated collections for some of the biggest high-end fashion brands in the world. The name gm3 stems from the ubiquitous gm (good morning) greeting that prevails in the decentralized finance & technology spaces. The number 3 represents the last digit in the term web3, which represents the 3rd major evolution of the internet.